Original title: Effectiveness and safety of a New Standardised TrEatment Protocol based on initial/early therapy with single-pill combinations of blood pressure-lowering drugs for improving blood pressure control (NewSTeP): Rationale, design of a randomized clinical trial and baseline characteristics of the trial participants
Rupasvi Dhurjati, Rashmi Pant, Amit Kumar, Anshika Mittal +19 · September 2026
High blood pressure is a top treatable risk factor for heart disease. Even though medicines exist, blood pressure control remains poor. Doctors often delay increasing treatments or hesitate to start multiple drugs together. Researchers in India set up a study called NewSTeP to address this issue. They designed a simple, fixed plan that uses single-pill combinationsOne pill that contains two or more blood-pressure-lowering drugs.. These are treatments that combine multiple blood pressure-lowering drugs into one single pill, making early therapy stronger and easier to take. In the trial, adults who need new or stronger treatment are split into two groups: one follows this new plan, and the other receives normal care. Over 6 months, researchers will track changes in blood pressure measured at home and watch for medication side effects. The study has finished enrolling 300 participants across nine sites, and the final results will show if this strategy effectively improves care.
Imagine you need to take two different vitamins every day, but they come in separate bottles. You often forget the second one or take it at the wrong time. Your doctor also waits to see if the first vitamin works before prescribing the second, so you spend weeks with only partial benefit. In this paper, the new treatment gives you both vitamins in a single pill from the start, and a clear schedule tells you exactly when to take it, making it much harder to miss a dose.
Hypertension is the leading preventable cause of heart disease worldwide, yet most people with it do not have their blood pressure under control. One major reason is that doctors hesitate to start multiple drugs at once, and patients struggle with taking many pills. This trial tests whether a single-pill combination started early, within a standardized treatment protocol, can make control easier and more effective for millions of patients in India.
The NewSTeP trial is a protocol paper; no results are reported. As an open-label trial, it is subject to bias from participants and clinicians knowing the treatment assignment. It is conducted in tertiary care centers in India, so findings may not generalize to primary care or other settings. The follow-up is only 6 months, which cannot capture long-term safety or cardiovascular outcomes.
Ask anything about this paper. Answers come from its abstract, and say so when the abstract doesn't cover your question.
Effectiveness and safety of a New Standardised TrEatment Protocol based on initial/early therapy with single-pill combinations of blood pressure-lowering drugs for improving blood pressure control (NewSTeP): Rationale, design of a randomized clinical trial and baseline characteristics of the trial participants — Rupasvi Dhurjati, Rashmi Pant, Amit Kumar et al. — medRxiv — doi:10.64898/2026.09.10.26362712
Abstract licence: CC BY
Explanation generated by Synthesis from the abstract — it is not the original paper. This is a preprint, so it hasn't necessarily been peer reviewed.